Comparison of the proliferation, cytotoxic activity and cytokine secretion function of cascade primed immune cells and cytokine-induced killer cells in vitro

Abstract

The present study aimed to compare the antitumor effects of cascade primed immune (CAPRI) cells and cytokine-induced killer (CIK) cells in vitro, through investigating cell morphology, proliferation, cytotoxic activity to tumor cells and the ability of these cells to secrete cytokines. Peripheral blood samples (50 ml) were obtained from three healthy volunteers and peripheral blood mononuclear cells (PBMCs) were obtained from each via Ficoll-Conray density gradient centrifugation. Each suspension of PBMCs (1×106/ml) was divided into two parts; CAPRI cells were obtained from one part through a series of induction, amplification and cytokine cultures, while CIK cells were obtained from the other part through induction with different cytokines. During the culture process, the proliferation and morphological changes were observed for the two cell types using Trypan blue staining. At day 14, the cytotoxic activity of the two cell types was examined through determining lactate dehydrogenase release in the presence of K562 leukemia cells and MCF-7 breast cancer cells. In addition, secretory levels of interferon (IFN)-γ and interleukin (IL)-2 were detected using enzyme-linked immunospot (ELISPOT) technology. The results revealed that at day 5 and 14 of culture, there were significantly fewer CAPRI cells compared with CIK cells (P<0.001), although the survival rate of each cell type was >95%. The cytotoxic activity of CAPRI cells towards the K562 cell line was effector-target ratio-dependent (40:1 and 20:1) with values of 55.1±3.25 and 35.0±2.65%, respectively, which were significantly reduced compared with the corresponding data in CIK cells, 60.0±3.03 and 39.7±3.42% (P=0.004 and 0.005, respectively). Furthermore, the cytotoxic activity of CAPRI cells towards MCF-7 cells were 71.5±3.06, 56.0±3.76 and 40.2±2.90% at effector-target ratios 40:1, 20:1 and 10:1, respectively. These data were significantly higher than the corresponding values in CIK cells, 65.4±3.86, 49.5±3.91 and 36.1±3.73% (P=0.002, 0.003 and 0.02, respectively). As determined using ELISPOT technology at different cell concentrations (1×106/ml and 5×105/ml), IFN-γ secretion levels, determined by the number of spot-forming cells, of CAPRI cells were 126.2±10.31 and 48.8±10.99, respectively, which were significantly reduced compared with those of CIK cells, 409.3±7.76 and 159.3±15.45, respectively (P<0.001). IL-2 secretion levels in CAPRI cells were 325.1±16.24 and 113.8±11.29 at 1×106/ml and 5×105/ml, respectively, which were significantly increased compared with CIK cells, 212.0±16.58 and 70.7±10.57, respectively (P<0.001). In conclusion, the present study demonstrated that CAPRI cells had a reduced proliferation rate compared with CIK cells as well as a less potent cytotoxic effect on K562 cells; however, the two cell types had potent cytotoxic activity towards solid tumor MCF-7 cells. In addition, CAPRI cells secreted lower levels of IFN-γ and increased levels of IL-2 compared with CIK cells. These results indicated that antitumor activities of CAPRI and C...

Cytokine-Induced Killer Cells as an Adoptive Cellular Immunotherapy Strategy for Hepatocellular Carcinoma

“…The onset of cells maturation, cluster-like formation, could be observed on day 7, while fully matured suspended CIK clusters could be observed on day 14. This goes with the results reported by Li et al [45], who cultured MNCs for 14 days and found that the cells began to proliferate within 3 days and became fully matured as colonies in suspension within 14 days. On the other hand, these findings were not in line with Bonanno et al [46], Niam et al [31], and Wei et al [38], who cultured human PBMCs for 21, 28, and 15 days, respectively, to reach the maturation stage.…”

“…The CIK cells' cytotoxic effect on cancerous cells showed variable degrees of efficacy in several tumors including malignant lymphoma either Hodgkin's disease or non-Hodgkin's lymphoma [49], hematological malignancies as acute myeloid and acute lymphocytic leukemia [50] and chronic lymphocytic leukemia [51]. Recent in vitro studies had further shown the potential activity of CIK cells differentiated from the blood of healthy or patient volunteers against breast cancer [30], pancreatic cancer [52], sarcomas [53], ovarian cancer [44], metastatic melanoma [54], glioblastoma or brain cancer [55], solid tumors [45], and gallbladder cancer [56]. In this study, the cytotoxic effect of CIK cells was investigated on HCC in vitro.…”

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer

“…Cytokine-induced killer cell-based therapy provides an immunotherapeutic approach involving anti-tumor effects via direct cell-cell-contact-mediated apoptosis and secretion of cytokines (118). To further boost the effects of cytokineinduced killer cells, the approach may be combined with tumor-specific dendritic cells presenting tumor antigens and orchestrating T-cell response.…”

Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients

“…Compared with other immune cells, CIK cells have greater proliferative capability, broader anti-tumor spectrum and stronger anti-tumor ability [ 3 , 9 ]. CIK cells’ tumoricidal ability relies on inducing tumor cell apoptosis through direct contact and secretion of cytokines such as IL-2, TNF-a and IFN-γ [ 10 ], and the cytotoxicity of CIK cells is not affected by immune inhibitors such as CsA and FK506 [ 11 ]. Dendritic cells (DC) are the most potent antigen-presenting cells [ 12 ].…”